Susilo Wagino MulyoThe intersection of metabolic health and sleep medicine has entered a new era with the rise of glucagon-like peptide-1 (GLP-1) receptor agonists. While medications such as semaglutide—marketed as Ozempic for…
Susilo Wagino MulyoThe landscape of obesity treatment has been fundamentally altered by the emergence of glucagon-like peptide-1 receptor agonists (GLP-1s). As these medications gain traction for their efficacy in promoting weight loss,…
Susilo Wagino MulyoThe intersection of weight management and sleep health has become a focal point of modern internal medicine, particularly as the prevalence of obstructive sleep apnea (OSA) continues to climb in…
Susilo Wagino MulyoThe U.S. Food and Drug Administration (FDA) has delivered a significant development in the treatment of obstructive sleep apnea (OSA), approving tirzepatide (Zepbound), a glucagon-like peptide-1 (GLP-1) receptor agonist, for…
Susilo Wagino MulyoThe landscape of sleep apnea treatment is undergoing a significant transformation with the emergence of Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications initially developed for type 2 diabetes.…
Hanik KholidahThe global wellness industry has seen a dramatic surge in the popularity of berberine, a bioactive alkaloid extracted from several different plants, including European barberry, goldenseal, and Oregon grape. Marketed…
